Company intelligence / Profile preview

Opaldia

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Opaldia is a UK-based healthcare company specializing in metabolic health and the management of Type 2 diabetes. The company provides diagnostic testing services and personalized health programs aimed at improving metabolic markers and potentially reversing Type 2 diabetes through lifestyle and dietary interventions. Their core offering includes the Opaldia Test, a comprehensive blood analysis that evaluates metabolic health, alongside clinical support from specialists. Opaldia's approach focuses on addressing the root causes of metabolic dysfunction rather than solely managing symptoms through medication.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Diagnostic testLifestyle intervention
Industry: Metabolite Diagnostics

Beyond the preview

Go deeper on Opaldia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Opaldia.

Explore the full profile